Xvivo Perfusion AB (publ)

Total Valuation

Xvivo Perfusion AB (publ) carries a market capitalization of 8.95B, placing it among publicly traded companies globally. Its enterprise value stands at 8.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Xvivo Perfusion AB (publ) currently has 31.50M shares outstanding.

Valuation Ratios

Xvivo Perfusion AB (publ) trades at a trailing price-to-earnings ratio of 79.98. The price-to-sales ratio is 10.82, and the price-to-book ratio stands at 31.62.

Enterprise Valuation

On an enterprise value basis, Xvivo Perfusion AB (publ) trades at an EV/EBITDA multiple of 124.97 and an EV/FCF ratio of 110.77. The EV/Sales ratio of 10.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 124.97 provides insight into valuation relative to core operating earnings.

Financial Position

Xvivo Perfusion AB (publ) maintains a current ratio of 4.81, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

Xvivo Perfusion AB (publ) posts a return on equity of 49.27 and a return on invested capital of 3.04.

Taxes

Over the trailing twelve months, Xvivo Perfusion AB (publ) has paid 8.52M in income taxes, reflecting an effective tax rate of 7.11.

Stock Price Statistics

Xvivo Perfusion AB (publ)'s stock has declined approximately -1.38889% over the past 52 weeks. The 50-day moving average sits at 273.74, while the 200-day moving average is 215.25.

Income Statement

Over the trailing twelve months, Xvivo Perfusion AB (publ) generated 822.93M in revenue and converted that into 111.38M in net income, yielding earnings per share of 3.52. EBITDA reached 69.58M, while operating income came in at 69.58M.

Balance Sheet

Xvivo Perfusion AB (publ) holds 323.00M in cash and equivalents against 110.81M in total debt, resulting in a net debt position of -322.99M. Total book value stands at 281.74M, with working capital of 612.49M providing operational flexibility.

Cash Flow

Xvivo Perfusion AB (publ) produced 78.51M in operating cash flow over the past twelve months.

Margins

Xvivo Perfusion AB (publ) operates with a gross margin of 74.87, reflecting its pricing power and cost economics. The operating margin of 8.46 and net profit margin of 13.53 provide insight into operational efficiency.

Dividends & Yields

Scores

Xvivo Perfusion AB (publ) posts an Altman Z-Score of 20.31, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.